Contributing Author: Rob Malone
Victoria “Vicky” Ann Michelis lived her life with an uncompromising moral compass. She was a woman who championed the underdog, cherished her community, and possessed an innate, razor-sharp ability to see through pretense. To those who knew her, she was not defined by the aggressive illness that eventually claimed her life; rather, she was defined by her tenacity, her empathy, and her refusal to stand idly by while others suffered.
Today, her spirit remains a driving force in the world of oncology. Through the Victoria Ann Michelis Fund, her legacy has been transformed into a catalyst for scientific innovation. By supporting the Cancer Research Institute (CRI), her fund is fueling the next generation of immunotherapy, seeking the breakthroughs that were unavailable during her own struggle.
The Landscape of Ovarian Cancer: A Silent Crisis
To understand the significance of the work supported by the Victoria Ann Michelis Fund, one must first confront the gravity of the disease. Ovarian cancer remains one of the most lethal malignancies affecting women worldwide. It is a complex, often silent, and highly aggressive category of disease.
The ovaries—the reproductive organs responsible for producing eggs and hormones—are the primary site, but researchers have increasingly identified the fallopian tubes as a common origin point for these tumors. Furthermore, the peritoneum, which lines the abdominal cavity, can host related malignancies. Because these organs are located deep within the pelvis, early-stage tumors often remain asymptomatic, leading to late-stage diagnoses where the disease has already metastasized.
Statistical Reality
The human cost is staggering. Global data from 2024 indicates that approximately 331,000 women were diagnosed with ovarian cancer, with over 200,000 succumbing to the disease. In the United States alone, the 2026 projections estimate 21,010 new cases and 12,450 deaths. These numbers represent not just statistics, but families and communities fractured by a disease that often leaves patients with limited, standardized, and frequently ineffective treatment pathways.
A Life Defined by Tenacity: A Chronology
Vicky’s journey was marked by a series of battles—both for herself and for the people she championed.
Early Advocacy and Personal Struggle
Vicky’s character was forged in the everyday interactions of her life. Whether she was working in a professional capacity or navigating social circles, she had an unerring instinct for the vulnerable. Rob Malone, her longtime friend, recalls, "If you were a bigwig and too impressed with yourself, she had very little regard for you. If you were a small person who was struggling, she was all about you."
This empathy became her primary weapon when, following symptoms of hypercalcemia, she was diagnosed with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). It is an exceedingly rare and aggressive form of cancer. Even in the face of this diagnosis, Vicky’s intellect took over. She transitioned from a patient into a researcher, meticulously investigating her options and demanding the best care possible.
The Cycle of Remission and Recurrence
After enduring years of exhaustive surgical interventions and intensive chemotherapy, Vicky reached a period of remission. During this "thumbs up" phase, she did not simply return to normalcy. She turned her focus outward, founding a small nonprofit dedicated to awareness and symptom recognition. She knew firsthand how subtle the indicators of ovarian cancer could be and wanted to spare others the trauma of a delayed diagnosis.
In 2017, the cancer returned. The subsequent years were a testament to her sheer will to live. She exhausted every available clinical trial and pushed her body through aggressive, high-risk treatments. Despite her best efforts, the disease proved relentless, and Vicky passed away in 2020.
Bridging the Gap: The Victoria Ann Michelis Fund
Vicky’s estate planning was a final act of agency. By entrusting Rob Malone with the creation of a charitable fund, she ensured that her resources would continue her life’s mission. The Victoria Ann Michelis Fund was established to support US-based nonprofits that mirror her values: aiding underserved children, providing care for the vulnerable, protecting animals, and, crucially, advancing cancer research.
Why the Cancer Research Institute?
Rob Malone’s partnership with the Cancer Research Institute (CRI) was not accidental. It was a direct response to the limitations Vicky faced during her own treatment.
"Vicky was frustrated that she kept being put down the same old chemotherapy paths for treatment, that there wasn’t something innovative or different that could have been done," Malone explains. He recognized that the traditional standard of care for ovarian cancer had stagnated. By supporting CRI, the fund is backing "bold ideas"—research that prioritizes immunotherapy and novel biological interventions over the "same old" clinical protocols.
Scientific Implications: The Future of Immunotherapy
The fund’s support is currently directed toward two high-impact areas within the CRI ecosystem: postdoctoral fellowships and data infrastructure.
Engineering the Immune System
One of the primary beneficiaries is Dr. Hyung Jun Kim, a CRI Irvington Postdoctoral Fellow. Dr. Kim’s research focuses on the reengineering of macrophages—white blood cells that act as the immune system’s "first responders."
In the context of solid tumors like those found in the ovaries, the tumor microenvironment is often "hostile" to immune cells. The cancer essentially builds a wall, suppressing the body’s natural defenses and making it difficult for the immune system to infiltrate and destroy the malignancy. Dr. Kim’s work aims to reprogram these macrophages, turning them from inactive or compromised cells into active anti-tumor agents. This represents a paradigm shift from conventional chemotherapy to a more nuanced, biological approach.
The CRI Discovery Engine: A Digital Revolution
Beyond individual fellowships, the Victoria Ann Michelis Fund has committed to the CRI Discovery Engine. This initiative is a landmark project in modern oncology. Traditionally, cancer research has been siloed; findings in one institution rarely communicate efficiently with findings in another.
The Discovery Engine is designed to bridge these gaps by creating a standardized, AI-ready data repository. By enabling researchers to compare findings across global institutions, this platform identifies patterns in tumor behavior that would be invisible to a single lab. Because ovarian cancer is a focus of the Discovery Engine, the potential for identifying new therapeutic targets is significantly higher than under traditional, fragmented research models.
A Legacy Beyond the Diagnosis
Vicky Michelis did not want to be a patient; she wanted to be a force for good. While her life was cut short, the impact of her choices is being felt in laboratories and clinics across the country.
The Victoria Ann Michelis Fund represents a transition from reactive patient advocacy to proactive scientific disruption. It is a testament to the idea that a single life, when propelled by generosity and intellectual courage, can fundamentally change the trajectory of medicine.
For the thousands of women currently navigating the ambiguity of an ovarian cancer diagnosis, this fund provides more than just financial support—it provides a glimpse of a future where treatment options are not limited to the status quo, and where survival is not a matter of luck, but a matter of scientific triumph.
Vicky’s story concludes, but her mission continues. Through the researchers she empowers and the data she helps curate, she remains, as she always was, a champion for those who need someone in their corner.
Help Advance Cancer Research
The fight against ovarian cancer requires sustained effort and innovative thinking. To learn more about how you can support research aimed at developing new, life-saving treatment options, visit the Cancer Research Institute. Your support helps ensure that more patients have the time, the tools, and the hope they deserve.
